# reload+after+2024-01-23 10:45:40.855280
address1§1050 Waltham Street
address2§Suite 302
city§Lexington
state§MA
zip§02421
country§United States
phone§617 314 6297
website§https://www.kerostx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
fullTimeEmployees§129
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jasbir S. Seehra Ph.D.', 'age': 67, 'title': 'President, CEO, Treasurer, & Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 985584, 'exercisedValue': 0, 'unexercisedValue': 32491092}, {'maxAge': 1, 'name': 'Mr. Christopher  Rovaldi M.Sc.', 'age': 49, 'title': 'Chief Operating Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 708749, 'exercisedValue': 0, 'unexercisedValue': 186355}, {'maxAge': 1, 'name': 'Dr. Simon  Cooper MBBS', 'age': 53, 'title': 'Chief Medical Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 654271, 'exercisedValue': 0, 'unexercisedValue': 244500}, {'maxAge': 1, 'name': 'Mr. Keith C. Regnante MBA', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 603240, 'exercisedValue': 0, 'unexercisedValue': 2827850}, {'maxAge': 1, 'name': 'Ms. Esther  Cho J.D.', 'title': 'Senior VP, General Counsel & Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Robin  Wagner', 'title': 'VP of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jennifer  Lachey Ph.D.', 'age': 50, 'title': 'Senior Vice President of Discovery', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 604740, 'exercisedValue': 0, 'unexercisedValue': 13395379}, {'maxAge': 1, 'name': 'Mr. John  Oram M.B.A.', 'title': 'Senior Vice President of Program & Portfolio Management', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§8
compensationRisk§9
shareHolderRightsRisk§7
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.223
priceToSalesTrailing12Months§180467.94
currency§USD
dateShortInterest§1702598400
forwardEps§-5.45
exchange§NGM
quoteType§EQUITY
shortName§Keros Therapeutics, Inc.
longName§Keros Therapeutics, Inc.
firstTradeDateEpochUtc§1586352600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a73338e2-0750-36db-8d66-d045f2fcde9f
gmtOffSetMilliseconds§-18000000
targetHighPrice§105.0
targetLowPrice§60.0
targetMeanPrice§81.89
targetMedianPrice§80.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§9
quickRatio§17.292
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
